ECSP056030A - Sistema terapéutico transdérmico estable a los rayos uv - Google Patents

Sistema terapéutico transdérmico estable a los rayos uv

Info

Publication number
ECSP056030A
ECSP056030A EC2005006030A ECSP056030A ECSP056030A EC SP056030 A ECSP056030 A EC SP056030A EC 2005006030 A EC2005006030 A EC 2005006030A EC SP056030 A ECSP056030 A EC SP056030A EC SP056030 A ECSP056030 A EC SP056030A
Authority
EC
Ecuador
Prior art keywords
absorbing agent
active substance
therapeutic system
transdermal therapeutic
matrix
Prior art date
Application number
EC2005006030A
Other languages
English (en)
Inventor
Jochen Schumacher
Manfred Suesse
Michael Dittgen
Stephan Mletzko
Jan-Peter Ingwersen
Langguth Langguth
Dirk Schenk
Hubert Kaffl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP056030A publication Critical patent/ECSP056030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El invento se refiere a un nuevo sistema terapéutico transdérmico estable a los rayos UV (TTS) que consiste en una capa de base, por lo menos una matriz que contiene sustancia activa y opcionalmente una película despegable y además un agente absorbedor de rayos UV, donde entre la capa de base y la matriz que contiene sustancia activa, que se encuentra más alejada de la superficie de la piel, se prevé por lo menos una capa adhesiva que contiene agente absorbedor de rayos UV y entre la capa adhesiva que contiene el agente absorbedor de rayos UV y la matriz que contiene sustancia activa, que está más alejada de la superficie de la piel, se prevé por lo menos una capa separadora que es impermeable a la sustancia activa e im-permeable al agente absorbedor de rayos UV. El sistema terapéutico transdérmico de la inven-ción posee gran estabilidad y no tiene las desventajas de los TTS que contienen sustancias activas sensibles a la luz tradicionales.
EC2005006030A 2003-02-21 2005-09-20 Sistema terapéutico transdérmico estable a los rayos uv ECSP056030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster

Publications (1)

Publication Number Publication Date
ECSP056030A true ECSP056030A (es) 2006-01-27

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006030A ECSP056030A (es) 2003-02-21 2005-09-20 Sistema terapéutico transdérmico estable a los rayos uv

Country Status (30)

Country Link
US (3) US8486443B2 (es)
EP (1) EP1594483B1 (es)
JP (1) JP4528296B2 (es)
KR (1) KR100704825B1 (es)
AR (1) AR043248A1 (es)
AT (1) ATE333271T1 (es)
AU (1) AU2004212675B2 (es)
BR (1) BRPI0407615B8 (es)
CA (1) CA2515918C (es)
CR (1) CR7952A (es)
CY (1) CY1105716T1 (es)
DE (1) DE502004000988D1 (es)
DK (1) DK1594483T3 (es)
EA (1) EA008098B1 (es)
EC (1) ECSP056030A (es)
ES (1) ES2270345T3 (es)
HR (1) HRP20050828B1 (es)
IL (1) IL170295A (es)
IS (1) IS2541B (es)
ME (2) MEP14008A (es)
MX (1) MXPA05008778A (es)
NO (1) NO336108B1 (es)
NZ (1) NZ541807A (es)
PE (1) PE20041028A1 (es)
PL (1) PL219030B1 (es)
PT (1) PT1594483E (es)
RS (1) RS50428B (es)
SI (1) SI1594483T1 (es)
UY (1) UY28189A1 (es)
WO (1) WO2004073696A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1594483T1 (sl) 2003-02-21 2006-12-31 Schering Ag UV-stabilni transdermalni terapevtski obliz
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
CN101005833A (zh) * 2004-08-20 2007-07-25 3M创新有限公司 具有半透明保护膜的透皮药物递送装置
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
JP2011528038A (ja) * 2008-07-14 2011-11-10 サーモディクス，インコーポレイテッド 医療用デバイスおよび核酸の送達方法
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
ES2617334T3 (es) 2010-09-06 2017-06-16 Bayer Intellectual Property Gmbh Parches transdérmicos de dosificación baja con liberación elevada de fármaco
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
IL260290B2 (en) 2015-12-30 2023-11-01 Corium Inc Systems and methods for long-term percutaneous administration
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (es) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
EP0394429B1 (de) 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend gestoden
EP0453396B1 (de) 1990-03-30 1995-12-13 Ciba SC Holding AG Lackzusammensetzungen
ATE120368T1 (de) 1990-05-17 1995-04-15 Hisamitsu Pharmaceutical Co Estradiol enthaltende transdermale zubereitung.
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
MX9101787A (es) 1990-10-29 1992-06-05 Alza Corp Formulaciones,metodos y dispositivos anticonceptivos transdermicos
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) * 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
EP0787488A4 (en) 1994-11-18 1998-06-03 Hisamitsu Pharmaceutical Co TRANSDERMAL ABSORBABLE PLASTER
JP3908795B2 (ja) 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
HU228434B1 (en) 1995-06-07 2013-03-28 Ortho Mcneil Pharm Inc Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Ｊｓｒ株式会社 光硬化性樹脂組成物
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) * 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
CA2287463A1 (en) 1997-04-16 1998-10-22 Munehiko Hirano Base composition for percutaneous absorption and percutaneously absorbable preparation containing the base composition
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
AU2978400A (en) 1999-02-02 2000-08-25 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
EP1197212A4 (en) 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
JP4841781B2 (ja) 1999-11-24 2011-12-21 アジル・セラピューティクス・インコーポレイテッド 改良された経皮的避妊薬送達系および方法
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
BRPI0109198B8 (pt) 2000-03-17 2021-05-25 Hisamitsu Pharmaceutical Co emplastro tendo um apoio
AU2001264256B2 (en) * 2000-06-13 2006-05-11 Hisamitsu Pharmaceutical Co, Inc Plaster
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
US20030225048A1 (en) 2002-03-11 2003-12-04 Caubel Patrick Michel Sulfatase inhibiting continuous progestogen contraceptive regimens
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
SI1594483T1 (sl) 2003-02-21 2006-12-31 Schering Ag UV-stabilni transdermalni terapevtski obliz
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
US7387753B2 (en) 2003-08-25 2008-06-17 Bfs Diversified Products, Llc Method and apparatus to monitor the compressive strength of insulation boards
KR101133459B1 (ko) 2003-09-11 2012-04-12 시바 홀딩 인크 헤테로상 중합 기술로 제조한 광 안정화제의 농축된 수계 생성물
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
KR101168449B1 (ko) 2003-12-12 2012-07-25 바이엘 파마 악티엔게젤샤프트 침투 증진인자가 필요없는 호르몬의 경피 전달계
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
KR20110082142A (ko) 2008-10-06 2011-07-18 밀란 테크놀로지즈 인코포레이티드 비정질 로티고틴 경피 시스템

Also Published As

Publication number Publication date
PT1594483E (pt) 2006-12-29
JP2006518348A (ja) 2006-08-10
RS50428B (sr) 2009-12-31
ATE333271T1 (de) 2006-08-15
PL378035A1 (pl) 2006-02-20
EP1594483A1 (de) 2005-11-16
BRPI0407615B1 (pt) 2018-02-14
AU2004212675A1 (en) 2004-09-02
ME00147B (me) 2010-10-10
EP1594483B1 (de) 2006-07-19
KR100704825B1 (ko) 2007-04-09
CY1105716T1 (el) 2010-12-22
BRPI0407615B8 (pt) 2021-05-25
MXPA05008778A (es) 2006-05-25
HK1085394A1 (zh) 2006-08-25
US20130226113A1 (en) 2013-08-29
KR20050103499A (ko) 2005-10-31
AR043248A1 (es) 2005-07-20
MEP14008A (en) 2010-06-10
US8486443B2 (en) 2013-07-16
CR7952A (es) 2006-02-06
AU2004212675B2 (en) 2006-06-01
EA008098B1 (ru) 2007-02-27
BRPI0407615A (pt) 2006-02-14
ES2270345T3 (es) 2007-04-01
HRP20050828A2 (en) 2006-03-31
JP4528296B2 (ja) 2010-08-18
HRP20050828B1 (hr) 2013-10-25
EA200501224A1 (ru) 2006-04-28
RS20050639A (sr) 2007-09-21
PL219030B1 (pl) 2015-03-31
PE20041028A1 (es) 2005-02-18
US20060251707A1 (en) 2006-11-09
DE502004000988D1 (de) 2006-08-31
NO336108B1 (no) 2015-05-18
IS2541B (is) 2009-09-15
CA2515918C (en) 2010-11-16
IL170295A (en) 2010-05-31
CA2515918A1 (en) 2004-09-02
IS8031A (is) 2005-09-15
SI1594483T1 (sl) 2006-12-31
NO20054321L (no) 2005-09-20
US20150335658A1 (en) 2015-11-26
DK1594483T3 (da) 2006-11-20
NZ541807A (en) 2009-07-31
WO2004073696A1 (de) 2004-09-02
US9095691B2 (en) 2015-08-04
UY28189A1 (es) 2004-04-30

Similar Documents

Publication Publication Date Title
ECSP056030A (es) Sistema terapéutico transdérmico estable a los rayos uv
CL2003002767A1 (es) Composicion oral que comprende una pelicula que contiene un material funcional, en un vehiculo, util para el cuidado oral.
PE40596A1 (es) Producto absorbente sanitario para la absorcion de liquidos corporales
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
ES2188648T3 (es) Copolimeros biodegradables y objetos de plastico que comprenden copo limeros biodegradables.
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
EA200400866A1 (ru) Ламинированный инсектицидный диспенсер
ES2123407B1 (es) Procedimiento y materiales para sanear recintos cargados con materiales contaminantes.
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
BR0313092A (pt) Sistema de liberação transdérmica aperfeiçoado
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
SE0300960D0 (sv) Material for packaging purposes
CR9483A (es) Sistema terapeutico transdermico solido con absorbedor uv
AR056268A1 (es) Tabletas que comprenden una sustancia biologicamente activa y un excipiente
CU23518A3 (es) Sistema terapéutico transdérmico estable a los rayos ultravioletas
GT200000013A (es) Composiciones extruidas livianas que contienen un portador ceramico liviano extruible, metodos de usode las mismas y procesos para su preparacion.
AR054012A1 (es) Sistema terapeutico transdermico para la adminstracion de analgesicos
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
DE60217369D1 (de) Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
CO5640059A2 (es) Uso de clorofila para el control de malos olores en articulos absorbentes desechables
GT200400261A (es) Forma de administracion transdermica, liquida o semisolida que contiene sustancia activa sensible a la luz, estable a los rayos ultravioletas
AR012169A1 (es) Un articulo absorbente
AR022956A1 (es) Sistema transdermal terapeutico y procedimiento para su fabricacion
ITTO990935A0 (it) Sistema per lo sviluppo rapido in luce ambiente di film radiografici d entali che consente il recupero del liquido di trattamento esausto. il
AR011772A1 (es) Una pelicula con capacidad para respirar, un articulo absorbente que incluye dicha pelicula, un proceso para formar dicha pelicula, una prenda medica que incluye la misma, un laminado con capacidad para respirar y un proceso para formar dicho laminado